USP13 dictates RAN turnover and vulnerability to ferroptosis in diffused large B cell lymphoma (DLBCL)

Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, is an aggressive form of lymphoma. It accounts for 40% of non-Hodgkin's adult lymphoma cases worldwide. The current standard treatment for DLBCL is CHOP. The poor prognosis of patients with DLBCL is related to the development of genetic mutations that lead to chemotherapy resistance. This topic mainly explores whether Spautin-1 can improve the sensitivity of DLBCL to chemotherapy drugs and the mechanism of synergistic effect. Overall design: To investigate the regulation of DLBCL cell line genes by small molecule inhibitors Spautin-1, we established a dosing model for DLBCL cell lines. We then performed gene expression profiling analysis using data obtained from RNA -seq. Comparative gene expression profiling analysis of RNA-seq data for SU-DHL-2 cells and its dosing group(Spautin-1,10 µM, 36 h).